The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
Selegiline is the oldest compound in this book — developed in Budapest in the 1960s, approved for Parkinson's disease in 1989, and still generating longevity research 35 years later. Its presence in a book about peptides and research chemicals reflects its unique position: a prescription pharmaceutical that the longevity community has adopted as a dopamine optimization and neuroprotective agent at doses far below its clinical range.
Joseph Knoll at Semmelweis University Budapest developed deprenyl (the racemic mixture) in the 1960s and then identified the L-enantiomer (selegiline) as the pharmacologically active and MAO-B selective form. Knoll's insight was pharmacologically profound for its time: MAO-B is the predominant MAO isoform in the brain; selectively inhibiting MAO-B would preserve dopamine and phenylethylamine without the catastrophic tyramine pressor response ('cheese effect') produced by non-selective MAO inhibitors like phenelzine or tranylcypromine. The selectivity was the entire clinical advance. When selegiline received FDA approval for Parkinson's disease in 1989 as Eldepryl (oral 5 mg bid), it became the first selective MAO-B inhibitor in clinical use — a milestone in neuropharmacology. The Emsam transdermal patch (approved 2006) extended the indication to major depressive disorder, using the transdermal route to achieve systemic concentrations sufficient for antidepressant effect while somewhat mitigating the first-pass hepatic metabolism that produces amphetamine metabolites.
Knoll's 1988 longevity data brought selegiline to the broader biohacking and longevity community: rats treated with deprenyl lived significantly longer than controls in multiple studies, with maximum lifespan extension — not just mean lifespan, but maximum. The subsequent work on the 'enhancer effect' theory (Knoll's hypothesis that the compound activates silent dopaminergic neurons beyond simple MAO-B inhibition) generated substantial controversy and ongoing research. The community use that followed — low-dose selegiline every few days for dopamine preservation, mood, and longevity — became one of the first modern nootropic/longevity protocols and directly preceded the contemporary peptide community's approach to this space.
THE CENTRAL TENSION
Selegiline is simultaneously a 50-year-old well-characterized pharmaceutical with FDA-approval, decades of clinical safety data, and a precise mechanistic understanding — and a compound whose longevity and nootropic applications are based on rat data and mechanistic inference that has never been fully validated in human controlled trials. The Parkinson's indication is Grade A evidence. The longevity application is Grade C (rat data). The neuroprotective claim is genuinely contested — DATATOP showed symptomatic benefit, not structural neuroprotection, a distinction that took years to fully appreciate. At low community doses (1-5 mg every 2-3 days), the compound has an excellent safety profile, no meaningful tyramine risk, and effects that are mechanistically coherent. At the standard Parkinson's clinical dose (10 mg/day), the amphetamine metabolites become more relevant and the risk profile changes somewhat. Understanding the dose-dependent selectivity is the most important pharmacological concept for safe community use.
Selegiline is metabolized by hepatic CYP2B6 and CYP3A4 to L-amphetamine (levoamphetamine) and L-methamphetamine (levomethamphetamine). The urinary recovery data: L-amphetamine 20-60% of dose; L-methamphetamine 9-30%. These are real metabolites in real quantities — this is not a trace finding. The critical pharmacological distinction: the amphetamine compounds in question are the L-enantiomers (levorotatory), not the D-enantiomers (dextrorotatory) that characterize pharmaceutical amphetamine (Adderall contains primarily d-amphetamine) and illicit methamphetamine (d-methamphetamine). The D-enantiomers have much greater CNS activity — higher blood-brain barrier penetration, greater potency at dopamine and norepinephrine transporters, stronger euphoriant/stimulant profile. L-methamphetamine is actually found in Vicks Inhaler as a nasal decongestant (phenylmethylpropanolamine isomer) — its CNS penetration and stimulant activity are substantially lower than d-methamphetamine. L-amphetamine has moderate CNS activity — less than d-amphetamine but not negligible at high doses.
Practical implications at community doses: at 1-5 mg selegiline every 2-3 days, the L-amphetamine and L-methamphetamine metabolite burden is very small. Most community users at low doses report no stimulant effects from the metabolites. At clinical Parkinson's doses (10 mg/day), some mild stimulant or activating effect is occasionally reported. The community concern about 'methamphetamine precursor' language is technically accurate but pharmacologically misleading — the L-enantiomers have a qualitatively different CNS profile from the controlled substance D-methamphetamine. However: at high doses, the L-amphetamine metabolite burden becomes clinically meaningful; and in drug testing contexts (employment, athletics, military), the metabolites can produce positive tests for amphetamine regardless of enantiomer form — this is a practical consideration for community users in tested environments.
Monoamine oxidase type B (MAO-B) is one of two isoforms of the mitochondrial enzyme monoamine oxidase (the other being MAO-A). MAO-B is the predominant form in the human brain — approximately 80% of brain MAO activity — and is primarily responsible for the oxidative deamination of dopamine, phenylethylamine (PEA), and benzylamine. MAO-B is expressed at especially high levels in serotonergic neurons, glial cells, and dopaminergic neurons of the substantia nigra and striatum. Selegiline binds irreversibly to the FAD-containing active site of MAO-B, forming a covalent adduct that permanently inactivates the enzyme. Recovery of MAO-B activity after selegiline discontinuation requires new enzyme synthesis — taking approximately 2-4 weeks. This long recovery time is why community protocols typically use intermittent dosing (every 2-3 days) rather than daily — the enzyme remains substantially inhibited between doses due to the irreversible mechanism.
By inhibiting MAO-B, selegiline reduces dopamine catabolism in the striatum and other dopaminergic brain regions. The normal fate of synaptic dopamine: reuptake via the dopamine transporter (DAT) → intracellular oxidation by MAO-B → DOPAC (3,4-dihydroxyphenylacetic acid) + hydrogen peroxide. Selegiline blocks the MAO-B step, preventing dopamine degradation after reuptake. The consequences: increased intracellular dopamine availability; reduced DOPAC production; reduced hydrogen peroxide generation (a key component of the neuroprotective mechanism). The hydrogen peroxide reduction is significant because dopamine oxidation is a source of oxidative stress in neurons — particularly relevant in Parkinson's disease where substantia nigra neurons with high dopamine turnover are selectively vulnerable to oxidative damage.
PEA (beta-phenylethylamine) is an endogenous trace amine that is also a substrate for MAO-B. Under normal conditions, PEA is extremely rapidly degraded by MAO-B (half-life minutes) — which is why dietary PEA (from chocolate, for example) produces no discernible CNS effect at normal consumption. When MAO-B is inhibited by selegiline, PEA plasma levels and brain concentrations rise dramatically. PEA has several pharmacological actions: stimulates dopamine and norepinephrine release from nerve terminals; inhibits dopamine and norepinephrine reuptake transporters (DAT, NET); activates the trace amine-associated receptor 1 (TAAR1) — a receptor increasingly implicated in mood regulation, psychostimulant effects, and antipsychotic mechanisms. The PEA elevation may contribute to selegiline's mood-elevating and cognitive-activating effects — effectively a mild endogenous amphetamine-like signal from accumulated PEA. This is distinct from the exogenous amphetamine metabolites (L-amphetamine, L-methamphetamine) from selegiline's propargylamine metabolism.
Beyond MAO-B inhibition, selegiline shows several neuroprotective mechanisms that are dose-independent and pharmacologically distinct from the enzyme inhibition: (1) Antioxidant effects — reduced hydrogen peroxide from dopamine metabolism; upregulation of antioxidant enzymes (superoxide dismutase, catalase) documented with chronic selegiline treatment; (2) Anti-apoptotic effects — selegiline prevents mitochondria-dependent apoptosis; a 2025 study (PMC11914425) identified suppression of protein disulfide isomerase (PDI) pro-apoptotic activity as a specific mechanism; (3) Neurotrophic factor upregulation — BDNF and NGF (nerve growth factor) increases documented in cell culture and animal models at sub-MAO-B inhibitory concentrations; this is part of the 'enhancer effect' hypothesis (see below); (4) MPTP protection — selegiline prevents the neurotoxic effects of MPTP (a dopaminergic neurotoxin) in rodent and primate models — one of the most cited preclinical neuroprotection findings.
Knoll proposed a mechanism for selegiline's longevity effects that goes beyond MAO-B inhibition: the 'catecholaminergic activity enhancer' (CAE) effect. According to this theory, selegiline at very low doses (below the MAO-B inhibitory threshold) activates silent or hypoactive dopaminergic and noradrenergic neurons — converting them from silent to spontaneously active. This activation is proposed to occur through a mechanism distinct from MAO-B inhibition, involving TAAR1 or other receptor pathways. The enhancer effect is supported by in vitro electrophysiology and behavioral data, and is the proposed explanation for why extremely low doses of deprenyl (0.001 mg/kg in rats — far below MAO-B inhibitory doses) produced lifespan extension and the cognitive improvements in aged rats. The enhancer theory remains contested — not definitively proven or disproven — but represents the most mechanistically sophisticated framework for understanding selegiline's effects beyond simple dopamine preservation.
Selegiline is FDA-approved for Parkinson's disease as adjunctive therapy. The evidence base: multiple RCTs confirming symptomatic benefit when added to levodopa, reducing 'on-off' fluctuations and extending the duration of levodopa action; the DATATOP trial; and decades of clinical experience. In Parkinson's: MAO-B inhibition reduces dopamine catabolism → more dopamine available at postsynaptic receptors → symptomatic improvement. This is Grade A evidence for the indication. Parkinson's disease patients benefit from selegiline as part of their treatment regimen — this is not contested.
DATATOP (Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism; Parkinson Study Group, 1989-1993): n=800 early Parkinson's patients; randomized to selegiline 10 mg/day, vitamin E (tocopherol), both, or neither; primary endpoint: time to disability requiring levodopa therapy. Early results: selegiline significantly delayed the need for levodopa by approximately 9 months. Initial interpretation: selegiline was slowing disease progression (true neuroprotection). Revised interpretation after longer follow-up: the delay in levodopa initiation reflected selegiline's symptomatic benefit masking disease progression — when selegiline was stopped in later follow-up, the apparent advantage disappeared. The longer DATATOP extension showed that on long-term follow-up, the mortality and disability trajectory in selegiline-treated patients was not significantly different from controls. Conclusion: DATATOP showed symptomatic benefit, not true structural neuroprotection. This distinction is critically important for the community: selegiline does not prevent neurodegeneration in Parkinson's patients, and the evidence for true neuroprotection in humans remains unproven.
Knoll J, et al. (1988 original; confirmed in multiple subsequent publications). Rats treated with L-deprenyl (0.25 mg/kg 3x/week) starting at middle age lived significantly longer than saline-treated controls — with increases in both mean and maximum lifespan. The maximum lifespan extension is biologically more significant than mean lifespan extension because it suggests an effect on the aging process itself rather than simply preventing disease. Key findings across the Knoll longevity research program: lifespan extension reproducible across multiple cohorts; tumor-manifestation-suppressing effect (reduced fibromyxosarcoma incidence); cognitive preservation in aging (old deprenyl-treated rats performed on cognitive tasks like young rats); Drosophila lifespan extension also documented. No equivalent human longevity controlled trial exists. The rat data is Grade C (consistent preclinical evidence from one research group's program). The community application of this data to human longevity protocols represents inference from animal research, not human clinical evidence.
Emsam (selegiline transdermal; 6 mg/24h, 9 mg/24h, 12 mg/24h; Somerset Pharmaceuticals): FDA-approved 2006 for major depressive disorder. At the 6 mg/24h patch dose, dietary tyramine restriction is not required — the transdermal route achieves systemic concentrations with lower first-pass hepatic activation of amphetamine metabolites and lower gastrointestinal MAO-A inhibition than oral formulations, maintaining MAO-B selectivity while providing antidepressant concentrations. At 9 and 12 mg/24h patches, dietary restrictions apply. Multiple RCTs confirmed efficacy vs placebo for MDD. This is the clearest evidence that selegiline's CNS mechanisms produce clinically meaningful antidepressant effect in non-Parkinson's patients — directly relevant to the community's mood/motivation application.
Application
Grade
Evidence
Key Limitation
Parkinson's disease (symptomatic)
A
Multiple RCTs; FDA approval; DATATOP; decades clinical use
Symptomatic benefit; true neuroprotection not proven
DATATOP neuroprotection claim
A (negative)
DATATOP — delay in levodopa initiation was symptomatic, not structural neuroprotection
Settled: DATATOP does NOT prove neuroprotection in humans
Major depressive disorder (Emsam transdermal)
A
Multiple RCTs; FDA approval 2006 for MDD
Transdermal route; 6 mg patch = no dietary restriction; 9/12 mg = dietary restriction required
Longevity / lifespan extension
C
Knoll rat studies 1988-2016; Drosophila lifespan data; multiple confirmatory rodent studies
Rat data only; no human controlled lifespan trial; from single research group's program
Cognitive preservation in aging
C
Knoll rat studies; aged rats perform like young on cognitive tasks with deprenyl treatment
Animal data; translation to humans unproven
Neuroprotection (MPTP model)
C (animal)
Robust protection against MPTP dopaminergic neurotoxicity in mice and primates
MPTP model; clinical translation unproven
The entire safety architecture of selegiline depends on one pharmacological relationship: the dose-dependent selectivity for MAO-B over MAO-A. Understanding this relationship is the most important clinical knowledge for safe use.
MAO-A metabolizes norepinephrine, serotonin, and tyramine. Non-selective MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) block both MAO-A and MAO-B, which is why they require strict dietary tyramine restriction — the 'cheese effect' or 'cheese reaction.' When MAO-A is inhibited, dietary tyramine (found in aged cheeses, cured meats, fermented foods) absorbed from the gut is not metabolized by intestinal MAO-A and reaches the systemic circulation, where it triggers massive catecholamine release from sympathetic nerve terminals → hypertensive crisis → potentially fatal. This is the mechanism that made older MAOIs the most dangerous antidepressants in clinical use. Selegiline at low doses maintains MAO-B selectivity because MAO-B and MAO-A have different binding site geometry, and selegiline's structure has much higher affinity for MAO-B. The approximate threshold: below ~10 mg/day oral selegiline, MAO-A is not significantly inhibited. Above this — at doses like 30-60 mg/day used in some historical studies — MAO-A inhibition becomes meaningful and dietary tyramine restriction becomes necessary.
THE DOSE THRESHOLDS — PRACTICAL SUMMARY
COMMUNITY LOW-DOSE (1-5 mg every 2-3 days): MAO-B inhibition predominates; MAO-A unaffected; no dietary tyramine restriction required; no serotonin syndrome risk from serotonin precursors (5-HTP) at reasonable doses; minimal amphetamine metabolite burden; excellent safety profile. CLINICAL PARKINSON'S DOSE (5 mg bid = 10 mg/day oral): MAO-B substantially inhibited; MAO-A begins to be affected at the high end; generally no tyramine restriction required at this dose (package insert does not require it); amphetamine metabolites clinically present but L-enantiomers with limited CNS activity. HIGH DOSES (>10 mg/day oral): increasing MAO-A inhibition; tyramine dietary restriction should be observed; serotonergic drug interactions become clinically significant. TRANSDERMAL EMSAM (6 mg/24h): no dietary restriction; 9/12 mg/24h: dietary restriction required. The community protocol of 1-5 mg every 2-3 days is well within the MAO-B selective range.
The serotonin syndrome concern: at any dose where MAO-A is inhibited, combining selegiline with serotonergic drugs (SSRIs, SNRIs, triptans, tramadol, meperidine, lithium, St. John's Wort) creates serotonin syndrome risk — potentially life-threatening. At low community doses (1-5 mg every few days), this risk is very low due to MAO-B selectivity. However: meperidine (Demerol) is absolutely contraindicated with selegiline at any dose — this combination can produce a fatal serotonin syndrome through a mechanism that does not require MAO-A inhibition. This is a hard contraindication that applies to low-dose community users.
Rasagiline (Azilect) is the second-generation selective irreversible MAO-B inhibitor, developed specifically to overcome selegiline's limitations. Understanding the comparison clarifies when selegiline remains the preferred choice.
Feature
Selegiline
Rasagiline
Chemical class
Propargylamine phenylethylamine derivative
Propargylamine indanamine derivative
MAO-B potency
Lower — 5 mg bid required for clinical effect
Higher — 1 mg/day adequate for Parkinson's
Amphetamine metabolites
Yes — L-amphetamine and L-methamphetamine
No — metabolized to aminoindan (no stimulant properties)
Cheese effect (tyramine)
Not at clinical doses (<10 mg/day oral); applies at higher doses
No cheese effect at any dose — no tyramine interaction documented
Drug testing
Can produce positive amphetamine test
No amphetamine cross-reactivity
Formulations
Oral tablet (Eldepryl 5 mg); ODT (Zelapar 1.25 mg); Transdermal patch (Emsam); generic selegiline widely available
Oral tablet only; no transdermal formulation; generic now available
Transdermal option for depression
Yes (Emsam; FDA-approved MDD)
No transdermal formulation; not FDA-approved for depression
Cost
Generic oral selegiline: inexpensive
Generic rasagiline: similar or slightly higher
Longevity/neuroprotective research base
Extensive (Knoll 1988-2016; multiple rat longevity studies; MPTP protection)
Less longevity-specific research; some neuroprotective data (ADAGIO trial for Parkinson's)
ADAGIO 'neuroprotection' data
N/A — DATATOP showed symptomatic, not structural
ADAGIO (2009): delayed-start design suggested possible disease modification at 1 mg; debated
The practical choice: for the community longevity/nootropic user who is concerned about the amphetamine metabolites or drug testing, rasagiline at 0.5-1 mg every few days is the cleaner option. It has no stimulant metabolites, no tyramine interactions at any dose, and equivalent or greater MAO-B selectivity. Selegiline retains advantages: the transdermal patch option (Emsam) for antidepressant effect; Knoll's longevity database is specifically for deprenyl/selegiline and the enhancer hypothesis was developed for this compound; and oral selegiline is very inexpensive as a generic. For the community user concerned primarily about MAO-B inhibition and dopamine optimization without metabolite concerns — rasagiline is the simpler choice.
The community protocol diverges significantly from the clinical Parkinson's dosing. Clinical Parkinson's use: 5 mg bid (10 mg/day). Community longevity/optimization use: 1-5 mg every 2-3 days. The rationale for intermittent low dosing: selegiline's irreversible MAO-B inhibition means enzyme activity remains substantially inhibited between doses even at 1-5 mg; daily low doses accumulate MAO-B inhibition over time; intermittent dosing allows partial MAO-B activity recovery between doses, potentially preserving some of the pulsatile MAO-B regulatory function; lower doses minimize the L-amphetamine/L-methamphetamine metabolite burden; 1-2.5 mg doses are in the range where Knoll's 'enhancer effect' at sub-MAO-B-inhibitory doses may be operative.
Protocol
Dose
Frequency
Context
Notes
Standard longevity
2.5-5 mg oral
Every 3-4 days
Adults 40+ interested in dopamine preservation and longevity
Knoll protocol-inspired; irreversible MAO-B means enzyme substantially inhibited between doses; inexpensive
Low dose enhancer
1-2.5 mg oral
Every 3-4 days
Community pursuing sub-MAO-B inhibitory 'enhancer effect'
Knoll's very low dose enhancer hypothesis; below clear MAO-B inhibitory threshold; theoretical mechanistic basis
Clinical Parkinson's adjunct (physician-supervised)
5 mg bid (10 mg/day)
Daily
Parkinson's disease management
FDA-approved dose; physician prescribed; standard clinical use
Antidepressant (transdermal Emsam)
6 mg/24h patch
Daily
Major depressive disorder
No dietary restriction at 6 mg patch; physician prescribed; FDA-approved MDD
Selegiline at any dose above 2.5 mg can produce mild insomnia or sleep disruption — particularly from the amphetamine metabolites' mild stimulatory effect. Morning dosing is standard for community protocols. Taking selegiline in the afternoon or evening risks sleep disruption. With or without food: oral selegiline can be taken with or without food; food reduces Cmax slightly and delays Tmax but does not meaningfully reduce bioavailability.
Meperidine (pethidine/Demerol) is absolutely contraindicated with selegiline at any dose. This combination can produce a fatal serotonin syndrome through mechanisms that include MAO-B inhibition even at low doses — the precise mechanism is not fully established but may involve meperidine's serotonin reuptake inhibiting properties combined with reduced serotonin degradation. This is not a low-dose exemption: meperidine + selegiline at any dose = hard contraindication. Anyone having elective surgery where opioids will be used should inform the anesthesiologist about selegiline use and request alternative opioids (morphine, oxycodone, hydromorphone are acceptable). Tramadol is also a concern — it has serotonergic properties and should be used with caution.
At community low doses (1-5 mg every few days) with maintained MAO-B selectivity, serotonin syndrome risk from SSRI combination is very low — MAO-A is not significantly inhibited and serotonin degradation is preserved. However: the pharmaceutical package insert states that SSRIs should not be used with selegiline without physician supervision. The practical reality: many Parkinson's patients take both selegiline and SSRIs under physician supervision without incident at clinical doses. At low community doses, the risk is minimal but not zero. If combining with SSRIs: start with the lowest selegiline dose; avoid escalating selegiline; be aware of serotonin syndrome symptoms (hyperthermia, agitation, clonus, hyperreflexia, diaphoresis). Avoid St. John's Wort — its serotonergic effects combined with even low-dose selegiline are unpredictable.
Selegiline metabolizes to L-amphetamine and L-methamphetamine, which can produce positive results on standard immunoassay drug tests for amphetamines. The tests typically screen for both L- and D-enantiomers. A positive screen can be confirmed by chiral GC-MS testing, which distinguishes L from D enantiomers — but confirmatory chiral testing is not universal in employment or probation drug testing. Community users who are subject to drug testing — employment, athletics (WADA), probation, military — should not use selegiline without understanding this risk fully. Rasagiline has no amphetamine metabolites and does not produce drug test positivity.
At low community doses: well tolerated; most users report no significant adverse effects; occasional reports of mild insomnia (if not dosed in the morning); very rare reports of mild headache or dizziness. At clinical Parkinson's doses: orthostatic hypotension; nausea; insomnia; dry mouth. The adverse effect profile at low doses is substantially better than at clinical doses.
Selegiline at doses ≤10 mg/day oral is MAO-B SELECTIVE — MAO-A is not significantly inhibited. Dietary tyramine restriction ('cheese reaction') applies only to non-selective MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) and to selegiline at doses above ~10 mg/day oral (or the higher Emsam patch doses of 9/12 mg/24h). At community low doses (1-5 mg every few days) and at standard Parkinson's clinical doses (10 mg/day), the package insert for Eldepryl does not require dietary tyramine restriction. No dietary restriction is required for Emsam at the 6 mg/24h starting dose. The community user at 2.5 mg every 3 days does not need to avoid aged cheese, cured meats, or fermented foods.
Selegiline metabolizes to L-methamphetamine — the L-enantiomer. L-methamphetamine is pharmacologically distinct from d-methamphetamine (the illicit stimulant): it has substantially less CNS stimulant activity, is less blood-brain-barrier penetrant, and has primarily peripheral sympathomimetic properties at typical concentrations produced by selegiline dosing. L-methamphetamine is the active ingredient in Vicks Inhaler decongestants. At low community doses, the L-methamphetamine metabolite burden is small. The concern is real and should not be dismissed — drug testing implications are genuine — but 'methamphetamine precursor = dangerous like illicit methamphetamine' is pharmacologically inaccurate.
The early DATATOP data was misinterpreted as showing neuroprotection. Subsequent analysis revealed the benefit was symptomatic — selegiline's dopamine-preserving effect masked the underlying disease progression signal (delayed the apparent need for levodopa without actually affecting the rate of neurodegeneration). Long-term follow-up showed no survival benefit and no difference in disability progression at full follow-up. DATATOP is NOT evidence for neuroprotection in Parkinson's patients.
Knoll's rat longevity data is real and reproducible within his research program. Rats treated with deprenyl at appropriate doses lived longer. Whether this translates to human lifespan extension has not been tested in a controlled human trial. The mechanisms proposed (enhanced dopaminergic neuron activity, antioxidant effects, anti-apoptotic effects) are biologically plausible. The rat-to-human translation of longevity pharmacology is notoriously unreliable — rapamycin extended lifespan in multiple species convincingly before human longevity benefit was established; other compounds looked promising in rodents and failed. The low-dose selegiline longevity protocol is rational and based on coherent mechanistic reasoning and consistent animal data — but it is not proven human longevity pharmacology.
Knoll J, et al. (1988). The striatal dopamine dependency of lifespan in male rats. Longevity study with (-)deprenyl. Mechanisms of Ageing and Development. 46(1-3):237-262. [The original longevity paper; rats treated with deprenyl 0.25 mg/kg lived significantly longer; the foundational community reference for selegiline longevity protocols.]
Knoll J, et al. (2016). Longevity study with low doses of selegiline/(-)-deprenyl and BPAP. Life Sciences. 167:57-64. PMID 27777099. [Most recent longevity study confirming very low dose enhancer effect; tumor-manifestation-suppressing effect; BPAP comparison.]
Parkinson Study Group. (1993). Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. NEJM. 328(3):176-183. [DATATOP extension confirming symptomatic rather than neuroprotective mechanism; the paper that clarified the DATATOP misinterpretation.]
Naoi M, Maruyama W, Inaba-Hasegawa K. (2012). Revelation in the neuroprotection of rasagiline and selegiline: the induction of distinct genes by different mechanisms. Expert Review of Neurotherapeutics. [Review of anti-apoptotic and neuroprotective mechanisms beyond MAO-B inhibition; BDNF/NGF upregulation; SOD and catalase upregulation.]
Zhang Z, et al. (2025). A novel neuroprotective mechanism of selegiline by suppressing the pro-apoptotic activity of protein disulfide isomerase. Published PMC11914425. [Most recent 2025 mechanism paper; PDI pro-apoptotic suppression as specific anti-apoptotic mechanism; mitochondria-dependent apoptosis prevention.]
Rascol O, Brooks DJ, et al. (2000). A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa (context for adjunct therapy including selegiline). NEJM. [Contextual; selegiline's place in Parkinson's treatment cascade.]
Amsterdam J, et al. (2004). Selegiline transdermal system (Emsam) in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-controlled study. Journal of Clinical Psychiatry. [Emsam MDD evidence; transdermal route advantages for MAO selectivity.]
Selegiline at low community doses is among the safest and most mechanistically coherent of any compound in this book. The longevity application is preclinical — rat data only. The dopamine optimization and mood applications are supported by mechanistic rationale and human clinical data from adjacent indications.
The honest summary: selegiline has been in clinical use for 35 years, has multiple FDA approvals, and a comprehensive safety characterization. At low community doses (1-5 mg every 2-3 days), the pharmacology is favorable: MAO-B selective (no tyramine risk, no dietary restriction); dopamine and PEA preserved; BDNF and neurotrophic factors upregulated; antioxidant and anti-apoptotic effects; L-amphetamine metabolites at clinically insignificant levels; excellent tolerability. The longevity application is supported by Knoll's extensive rat longevity program, mechanistically coherent, and broadly used in the evidence-based longevity community (Aubrey de Grey, Life Extension Foundation, and others have historically recommended it) — without a single human controlled lifespan trial. The DATATOP lesson should be remembered: biologically plausible mechanisms and biomarker improvements do not always translate to human clinical outcomes. At the same time, for a compound at 1-5 mg every few days with a 35-year safety record in millions of patients at higher doses, the risk-benefit calculation for longevity-motivated use is favorable compared to most compounds in this book.
— End of Selegiline —
THE PEPTIDE BIBLE | Selegiline | For Research & Educational Purposes Only
Selegiline: L-deprenyl; (-)-deprenyl; propargylamine phenylethylamine derivative; MW 187 Da; oral tablet or ODT or transdermal patch. Developed by Joseph Knoll, Semmelweis University Budapest, 1960s. FDA-APPROVED: Eldepryl (5 mg oral bid; Parkinson's adjunct); Zelapar (1.25 mg ODT; Parkinson's); Emsam (transdermal 6/9/12 mg/24h; major depressive disorder 2006). MECHANISM: Irreversible MAO-B inhibitor; MAO-B = primary brain MAO (80%); catabolizes dopamine, PEA, benzylamine; selegiline blocks irreversibly → dopamine preserved → DOPAC↓ → H₂O₂↓ (oxidative stress↓). PEA ACCUMULATION: MAO-B inhibition → PEA↑ → dopamine + NE release ↑ + TAAR1 activation = mood/motivation enhancement. NEUROPROTECTIVE MECHANISMS: antioxidant (SOD↑, catalase↑); anti-apoptotic (PDI pro-apoptotic suppression, 2025); BDNF/NGF upregulation; MPTP protection in rodent/primate models. ENHANCER EFFECT (Knoll theory): sub-MAO-B doses may activate silent dopaminergic neurons; contested but supported by in vitro electrophysiology. MAO-B SELECTIVITY: below ~10 mg/day oral = MAO-B selective; no tyramine restriction; no cheese effect; above = MAO-A inhibition begins. COMMUNITY DOSES (1-5 mg q2-3 days): well within MAO-B selective range; no dietary restriction; minimal amphetamine metabolite burden; excellent tolerability. DATATOP CLARIFICATION: early data misinterpreted as neuroprotection; delayed levodopa need was symptomatic masking; true structural neuroprotection NOT proven in humans. LONGEVITY DATA (Grade C): Knoll 1988 rat longevity studies; deprenyl-treated rats lived longer (mean + maximum lifespan); Drosophila confirmation; no human controlled lifespan trial. MDD (Grade A): Emsam transdermal; multiple RCTs; FDA-approved; 6 mg/24h = no dietary restriction. AMPHETAMINE METABOLITES: L-amphetamine (20-60% urinary) + L-methamphetamine (9-30%); L-ENANTIOMERS (not d-enantiomers); L-methamphetamine = Vicks Inhaler ingredient; substantially lower CNS activity than d-methamphetamine; drug testing positive possible regardless of enantiomer form. MEPERIDINE: ABSOLUTE CONTRAINDICATION at any dose. SSRI at low community doses: low risk; avoid St. John's Wort. vs RASAGILINE: more potent MAO-B inhibitor; no amphetamine metabolites; no tyramine at any dose; no drug testing concern; less longevity-specific research base. COMMUNITY PROTOCOL: 2.5-5 mg oral every 3-4 days; morning; generic inexpensive. WADA: not on prohibited list (not an anabolic agent; not S2). No HPTA suppression.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.